GlassScriptPhysician profile
Brett A Poisson
NPI 1255383337
$708.89
in general payments reported to CMS, 2019-2025
12 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $25.85 · 2023: $52.47 · 2024: $287 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $394 · Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $393.79 |
| Food and Beverage | $153.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $175.42 | 2019-2025 | Imfinzi |
| Aveo Pharmaceuticals, INC. | $144.99 | 2024-2025 | |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Glaxosmithkline, LLC. | $56.12 | 2025 | Blenrep, Ojjaara |
| Genentech USA, INC. | $53.45 | 2025 | |
| Acrotech Biopharma INC. | $41.79 | 2021-2023 | Beleodaq |
| Tactile Systems Technology INC | $38.51 | 2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $28.80 | 2019 | |
| Amgen INC. | $24.61 | 2023 | Blincyto |
| Novartis Pharmaceuticals Corporation | $17.43 | 2024 | |
| Sobi, INC | $16.85 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Poisson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.